The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the ...
Dans le cadre de l'ambition de Sanofi de développer un portefeuille diversifié de vaccins parmi les meilleurs de leur catégorie, l'entreprise ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with ...
Sanofi and Novavax signed a licensing agreement that includes commercialising a combined Covid-19 and flu shot. Read more at ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
STORY: Shares of vaccine maker Novavax spiked as much as 146% on Friday, after announcing it had struck a licensing deal with ...